PER® New York Lung Cancer Symposium

Benjamin Herzberg, MD, discusses the management challenges associated with STK11/KEAP1-mutated tumors, SMARCA4-deficient undifferentiated tumors, and NUT carcinoma.

Erminia Massarelli, MD, PhD, MS, discusses the clinical presentation and management of Lambert–Eaton myasthenic syndrome in the context of small cell lung cancer.

Alexander Drilon, MD, summarized approaches to TKI selection in NSCLC displaying oncogenic driver alterations for both TKI-pretreated and -naive patient populations.

Gregory J. Riely, MD, PhD, discusses targeted approaches for BRAF V600E, MET exon 14, and KRAS G12C mutations in metastatic NSCLC.

Charles M. Rudin, MD, PhD, discussed evolving standards of care and emerging therapeutics of interest in the SCLC treatment paradigm.

Soo-Ryum (Stewart) Yang, MD, discusses biomarkers for ADCs, the actionability of tumor suppressor genes, and the advent of computational pathology.

Benjamin P. Levy, MD, discusses advances with ADCs in lung cancer during the 20th Annual New York Lung Cancers Symposium.

Christine Hann, MD, PhD, discusses how recently presented SCLC data inform treatment decision-making across the LS-SCLC and ES-SCLC settings.

Thomas Marron, MD, PhD, discusses how findings from the DeLLphi-303 trial are shaping the use of tarlatamab across treatment settings in small cell lung cancer.

Hossein Borghaei, DO, MS, discusses the importance of determining the most suitable treatment for patients with non–small cell lung cancer through the use of biomarker testing.

Stephen V. Liu, MD, discusses the benefits of conducting biomarker testing for patients with advanced non–small cell lung cancer and highlights the importance of waiting for the results before selecting a targeted treatment.

Stephen V. Liu, MD, discusses strategies for treatment and disease management for patients with advanced non–small cell lung cancer who are awaiting biomarker test results.

Ongoing research evaluating combination therapies for the frontline treatment of patients with EGFR-mutated non–small cell lung cancer could help improve survival outcomes for this patient population.

Nicholas C. Rohs, MD, delves into the details of the case study a patient who had a lung cancer relapse detected following a referral to a dermatologist due to pityriasis rubra pilaris.

Nicholas C. Rohs, MD, discusses a case study that he presented during the Interesting Cases session at the 18th Annual New York Lung Cancers Symposium®.

Benjamin Philip Levy, MD, discusses antibody-drug conjugates under investigation in patients with non–small cell lung cancer.

While there are considerable barriers to incorporating comprehensive genotyping, the use of circulating tumor DNA offers an improvement in molecular testing—and doing so earlier can accelerate the time to treatment and improve survival for patients with lung cancer.

As treatments for patients with stage IV non–small cell lung cancer continue to evolve, patients with PD-L1–negative disease represent a unique cohort and chemotherapy/immunotherapy or immunotherapy doublet regimens appear to be effective.

Although the emergence of immunotherapy have created additional treatment options for patients with various types of cancer, these agents are associated with significant toxicities and immune-related adverse effects.

Balazs Halmos, MD, discusses the importance of testing for HER2 mutations and exon 20 insertions, which are emerging new targets in non–small cell lung cancer, and how fam-trastuzumab deruxtecan-nxki meets needs for patients with HER2-mutant disease.

Mark G. Kris, MD, discusses the role of immunotherapy in patients with non–small cell lung cancer without driver mutations.

In treating patients with locally advanced non–small cell lung cancer, one must consider multiple factors when deciding whether to treat them with immunotherapy or a targeted approach, even though the optimal treatment sequence has yet to be definitively established.

Osimertinib remains the preferred first-line therapy for patients with EGFR-mutated non–small cell lung cancer. However, for those with classic EGFR mutations, the day is fast approaching when physicians will add chemotherapy to first-line treatment with the EGFR TKI based on ctDNA results.

Investigators are harnessing comprehensive molecular profiling to detect new targets, optimize existing treatment regimens, and develop novel therapies for patients with EGFR and MET exon 20–insertion positive non–small cell lung cancer.

Ashish Saxena, MD, PhD, discusses a challenging case of a patient with non–small cell lung cancer.

Marjorie G. Zauderer, MD, discusses the importance of optimizing care for patients with mesothelioma.

Although next-generation TKIs have helped to overcome resistance in EGFR-mutated non–small cell lung cancer, a more complete understanding of resistance mechanisms may lead to the ability to overcome resistance to the next generation of these drugs.

The era of direct inhibitors to treat KRAS G12C-mutated non-small cell lung cancer has arrived in the clinic.